Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• The ATM protein is crucial for DNA damage response and cell cycle control.
• Targeting ATM presents a potential cancer therapy strategy, but normal tissue toxicity is a concern.

Purpose of the Study:

• To evaluate the efficacy and biocompatibility of a novel delivery system for ATM siRNA in breast cancer treatment.

Main Methods:

• Development of a liposomal-encapsulated, gene-specific ATM siRNA delivered via a porous silicon-based multistage vector (MSV/ATM).
• Treatment of MDA-MB-231 orthotopic breast cancer tumors in nude mice with MSV/ATM.
• Assessment of ATM expression, tumor growth inhibition, and immune response (cytokines, chemokines, CSFs).
• Evaluation of systemic toxicity through body weight, hematology, blood biochemistry, and organ histology.

Main Results:

• Biweekly MSV/ATM treatment suppressed ATM expression and inhibited tumor growth in mice.
• MSV/ATM did not trigger acute immune responses at therapeutic doses.
• Extended treatment (4 weeks) showed no significant systemic toxicity or adverse effects on major organs.

Conclusions:

• MSV/ATM demonstrates biocompatibility and efficacy in inhibiting breast cancer growth.
• The developed delivery system warrants further preclinical investigation for therapeutic potential.